Research programme: metabolic disease therapeutics - Galmed Medical Research
Latest Information Update: 16 Jul 2016
At a glance
- Originator Galmed Medical Research
- Class Bile acids and salts; Fatty acids
- Mechanism of Action Cholesterol inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Lipid metabolism disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Lipid-metabolism-disorders in Israel (PO)
- 10 Nov 2008 Preclinical trials in Lipid metabolism disorders in Israel (PO)